Glasgow-based Researchers Develop 'Ground-Breaking' Blood Test
Main Category: Multiple SclerosisArticle Date: 07 Oct 2008 - 5:00 PDT
| Patient / Public: | ![]() |
3.5 (10 votes) |
| Healthcare Prof: | ![]() |
|
| Article Opinions: | 1 posts |
A Glasgow-based research lab has announced what it claims to be a major breakthrough in the treatment of progressive multiple sclerosis (MS).
Glasgow Health Solutions (GHS), headed by Dr Tom Gilhooly, has developed Tyscore Assay, a blood test which detects the chemicals associated with the deterioration of nerve cells in people with MS.
The research team says the blood test will track the progression of MS, allowing doctors to pinpoint when patients are about to enter the next deteriorating phase of the condition.
Researchers used the test to measure the level of nitrotyrosine - the indicator of cell damage and inflammation seen in people with MS. They then used this as a biomarker for peroxynitrite activity which is thought to cause the deteriorating nerve damage in MS.
Dr Laura Bell, Research Communications Officer at the MS Society, said: "Yes, there is some science that suggests nitrotyrosine levels are raised in people with MS, but its value as a biomarker simply has not been validated and therefore interpretation of the results would be open to question.
"Also, there are currently no biomarkers known to predict MS, either in the blood or urine and no drugs to suppress nerve loss or indeed progression in secondary progressive MS or primary progressive MS anyway, so a positive result would not lead to a change in treatment or diagnosis.
"It's also worth remembering that nitrotyrosine levels could be induced by a number of different things including infections. People with progressive MS are more likely to get infections, particularly urinary tract infections, and this would confuse the results.
"The MS Society is among others carrying out early-stage research trying to find biomarkers for MS. A simple blood or urine test would of course be preferable to the current lumbar punctures or expensive MRI scans."
MS Society
Visit our multiple sclerosis section for the latest news on this subject.
MLA
13 Feb. 2012. <http://www.medicalnewstoday.com/releases/124515.php>
APA
http://www.medicalnewstoday.com/releases/124515.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Visitor Opinions In Chronological Order (1)
Glasgow-based Researchers Develop 'Ground-Breaking' Blood Test
posted by AH on 8 Oct 2008 at 8:09 amMuch here to cause concern. Apart from the fact that the value of the biomarker is unproven, what does Dr Gilhooly's comment "ensuring accurate and timely treatment of patients with the progressive forms of MS" mean? There is no treatment as yet.
Similarly "it can detect when a patient is entering the active phases of the disease" suggests this is a point when something can be done that currently isn't. Yet there are no available drugs that work on the progressive forms of MS.
Glasgow Health Solutions seems to also operate as a shop for supplements. Is this relevant to answering these questions?
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




